Patents Assigned to deCODE genetics ehf.
  • Sequence Variants Associated with Prostate Specific Antigen Levels
    Publication number: 20170191134
    Abstract: Certain sequence variants have been found to be useful for correcting Prostate Specific Antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.
    Type: Application
    Filed: August 8, 2016
    Publication date: July 6, 2017
    Applicant: deCODE genetics ehf
    Inventors: Julius Gudmundsson, Daniel Gudbjartsson, Patrick Sulem
  • Genetic susceptibility variants associated with cardiovascular disease
    Patent number: 9617597
    Abstract: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: April 11, 2017
    Assignee: deCode Genetics ehf
    Inventors: Anna Helgadottir, Gudmar Thorleifsson, Andrei Manolescu
  • Genetic variants for breast cancer risk assessment
    Patent number: 8951735
    Abstract: The invention pertains to certain genetic variants that have been determined to be susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: February 10, 2015
    Assignee: deCODE Genetics ehf.
    Inventors: Simon Stacey, Patrick Sulem
  • Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
    Patent number: 8883833
    Abstract: The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: November 11, 2014
    Assignee: Decode Genetics EHF
    Inventors: Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Munagala Rao
  • GENETIC VARIANTS FOR PREDICTING RISK OF BREAST CANCER
    Publication number: 20140329719
    Abstract: The invention pertains to certain genetic variants that have been determined to be susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kit, medium and apparatus useful for assessing risk of breast cancer.
    Type: Application
    Filed: June 14, 2012
    Publication date: November 6, 2014
    Applicants: ILLUMINA, INC., DECODE GENETICS EHF
    Inventors: Patrick Sulem, Simon Stacey
  • 4-(or 5-) substituted catechol derivatives
    Patent number: 8877816
    Abstract: Compounds of the formula: are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: November 4, 2014
    Assignee: Decode Genetics EHF
    Inventors: Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov
  • Genetic variants contributing to risk of prostate cancer
    Patent number: 8865400
    Abstract: The present invention is characterized by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: October 21, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Julius Gudmundsson, Patrick Sulem
  • SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
    Publication number: 20140275553
    Abstract: The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: deCODE genetics ehf
    Inventors: Jasbir SINGH, Mark E. GURNEY, Alex BURGIN, Alexander KISELYOV, Munagala RAO
  • Susceptibility variants for lung cancer
    Patent number: 8828657
    Abstract: The present invention discloses certain genetic variants as susceptibility variants for lung cancer. The invention relates to methods of risk assessment using such variants. The invention further relates to kits for use in risk assessment of lung cancer.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: September 9, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Thorunn Rafnar, Thorgeir E. Thorgeirsson, Patrick Sulem, Frank Geller
  • GENETIC VARIANTS ON CHR 11Q AND 6Q AS MARKERS FOR PROSTATE AND COLORECTAL CANCER PREDISPOSITION
    Publication number: 20140248615
    Abstract: It has been discovered that certain polymorphic markers on chromosome 6 and chromosome 11 are indicative of a susceptibility to prostate cancer and colon cancer. The invention describes diagnostic applications for determining a susceptibility to cancer using such markers, as well as kits for use in such applications.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 4, 2014
    Applicant: deCODE Genetics ehf.
    Inventors: Steinunn Thorlacius, Patrick Sulem, Julius Gudmundsson
  • Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
    Patent number: 8808985
    Abstract: The present invention discloses certain genetic variants as susceptibility variants for peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA). The invention relates to risk management using such variants. The invention further relates to kits for use in risk assessment of PAD and AAA.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: August 19, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Thorgeir Thorgeirsson, Patrick Sulem, Frank Geller, Kristinn P. Magnusson
  • GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION, ATRIAL FLUTTER, AND STROKE
    Publication number: 20140227693
    Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Application
    Filed: January 13, 2014
    Publication date: August 14, 2014
    Applicant: deCODE Genetics ehf.
    Inventors: Anna Helgadottir, Daniel Gudbjartsson
  • Genetic markers for risk management of atrial fibrillation and stroke
    Patent number: 8795963
    Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: August 5, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Hilma Holm, Daniel Gudbjartsson
  • Genetic markers associated with risk of diabetes mellitus
    Patent number: 8796182
    Abstract: The invention relates to variants that predispose to risk of type 2 diabetes, basal cell carcinoma and breast cancer. It has been discovered that certain genetic variants confer risk of these diseases when inherited from one parent, but not the other. The invention provides methods of disease management, including diagnostic methods, utilizing such parental origin effects.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: August 5, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Valgerdur Steinthorsdottir, Gudmar Thorleifsson, Daniel Gudbjartsson, Gisli Masson, Augustine Kong
  • Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
    Patent number: 8791267
    Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: July 29, 2014
    Assignee: Decode Genetics EHF
    Inventors: Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Adalie Motta, Gary Schiltz, Georgeta Hategan, Timothy Hagen
  • GENETIC VARIANTS ON CHR 5P12 AND 10Q26 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT
    Publication number: 20140179546
    Abstract: The invention pertains to certain genetic variants on Chr5p12 and Chr10q26 as susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased and/or decreased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Application
    Filed: October 9, 2013
    Publication date: June 26, 2014
    Applicant: deCODE Genetics ehf.
    Inventors: Simon Stacey, Patrick Sulem, Andrei Manolescu
  • Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
    Patent number: 8697360
    Abstract: It has been discovered that certain polymorphic markers on chromosome 6 and chromosome 11 are indicative of a susceptibility to prostate cancer and colon cancer. The invention describes diagnostic applications for determining a susceptibility to cancer using such markers, as well as kits for use in such applications.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: April 15, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Steinunn Thorlacius, Patrick Sulem, Julius Gudmundsson
  • GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF THYROID CANCER
    Publication number: 20140087961
    Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Application
    Filed: March 16, 2012
    Publication date: March 27, 2014
    Applicants: ILLUMINA INC., deCODE Genetics ehf.
    Inventors: Patrick Sulem, Julius Gudmundsson
  • VARIANTS PREDICTIVE OF RISK OF GOUT
    Publication number: 20140080727
    Abstract: Markers on chromosome 19q13, in particular, markers in the ALDH16A1 gene, are associated with risk of gout in humans. Diagnostic applications using the markers, such as determining the susceptibility to Gout, are described.
    Type: Application
    Filed: February 9, 2012
    Publication date: March 20, 2014
    Applicants: Illumina Inc., deCODE Genetics ehf.
    Inventor: Patrick Sulem
  • Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke
    Patent number: 8637244
    Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: January 28, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Anna Helgadottir, Daniel Gudbjartsson